Navigation Links
Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
Date:3/5/2009

mor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will satisfy Nasdaq's conditions for continued listing on The Nasdaq Capital Market, that any potential appeal or hearing for a stay of delisting from The Nasdaq Capital Market will be successful, or that the Company's common stock will remain listed on The Nasdaq Capital Market; that the Company will complete cost-effective clinical trials or meet as anticipated the development timelines for the drug candidates in its pipeline, including Zerenex and KRX-0401, to help generate greater interest in the market for its common stock; that our statements regarding our balance sheet, operating results and 2009 cash burn rate will reflect our actual results; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
4. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
7. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
10. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  Varian Medical Systems (NYSE: VAR ), world ... its commitment to sustainability with inclusion on a prestigious list ... ranked healthcare equipment company among the Corporate Knights Global 100 ... Forum at Davos, Switzerland . ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer ... - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines ... forecasting of revenues. , Browse 152 market data ... TOC on “Service Quality Management (SQM) and Telco Customer ...
(Date:12/24/2014)... Texas , Dec. 24, 2014  Vermillion, Inc. ... on gynecologic disease, announced today that the Company ... including Oracle Investment Management, Jack W. Schuler ... Total proceeds were $10.5 million, before offering expenses.  ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
Breaking Biology Technology:Varian Honored Among World's 100 Most Sustainable Corporations 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... CA, March 18, 2011 Cytokinetics, Incorporated (Nasdaq: CYTK) ... March 18, 2011 issue of the journal Science ... investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic ... with systolic heart failure. This publication reveals, for ...
... 17, 2011 Genomic Health, Inc. (Nasdaq: ... the Onco type DX® test in early-stage breast ... Breast Cancer Conference in St. Gallen, Switzerland.  The studies ... of a patient,s Recurrence Score® (RS) result changed physicians, ...
... Delta Point, Inc., a consulting firm that specializes in ... Ed Weimer as Executive Account Director. Weimer has gained ... highly motivate, develop and inspire his teams to attain ... to the organization,s goals. Delta Point CEO ...
Cached Biology Technology:Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 2Cytokinetics announces fundamental research in cardiac myosin activation in the journal Science 3Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 2Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 3Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 4Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 5Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 6Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 7Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test 8Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E - ... authentication solutions, today announced it will showcase its EyeLock ID ... by the Department of Energy,s Oak Ridge National Laboratory ... Show . EyeLock,s iris identity authentication technology is being used ...
(Date:1/22/2015)... , Jan. 16, 2015  A man-made form of ... and other mental capabilities in adults with mild cognitive ... study led by researchers at Wake Forest Baptist Medical ... diagnosed with amnesic mild cognitive impairment (MCI) or mild ...
(Date:1/22/2015)... NEW YORK and POINT ROBERTS, Washington ... global news source covering leading sectors including technology and tech ... Personal Privacy marketplace featuring master pickpocket and security consultant ... wallet is stolen and talks about the Wocket™ biometric smart ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... delivered by cesarean section have an increased risk of developing ... Study (MoBa) suggests that children delivered by cesarean section have ... This was particularly seen among children without a hereditary tendency ... 37 000 participants in the MoBa study were used to ...
... Bladder cancer, most frequently caused by smoking and exposure to ... most common forms of cancer in men,and women in the ... in stage T1 or less and have not invaded the ... (transurethral resection) and the burning away of tumors with high ...
... Going out to eat has become a major part ... foods in large portions at restaurants can contribute to excess ... the January/February 2012 issue of the Journal of Nutrition ... and still lose weight. Investigators from The University ...
Cached Biology News:Tapping the body's own defenses, researchers look to cutting-edge gene therapy for bladder cancer 2Would you stop eating out to lose weight? 2
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Biology Products: